Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Digitalis and verapamil in atrial fibrillation and flutter. Is verapamil now the preferred agent?

× No keyword cloud information.

73 in total

1. Effects of verapamil on electrophysiological properties of anomalous atrioventricular connexion in Wolff-Parkinson-White syndrome.

Authors: R A Spurrell; D M Krikler; E Sowton
Journal: Br Heart J Date: 1974-03

2. Effects of agents which inhibit the slow channel on sinus node automaticity and atrioventricular conduction in the dog.

Authors: D P Zipes; J C Fischer
Journal: Circ Res Date: 1974-02 Impact factor: 17.367

3. Effect of propranolol on exercise tolerance of patients with atrial fibrillation.

Authors: R W Brown; A J Goble
Journal: Br Med J Date: 1969-05-03

4. Drugs and the heart. III. Calcium antagonists.

Authors: L H Opie
Journal: Lancet Date: 1980-04-12 Impact factor: 79.321

Review 5. Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil.

Authors: M R Rosen; A L Wit; B F Hoffman
Journal: Am Heart J Date: 1975-05 Impact factor: 4.749

6. Conversion of atrial fibrillation and flutter by propranolol.

Authors: S Wolfson; M V Herman; J M Sullivan; R Gorlin
Journal: Br Heart J Date: 1967-05

7. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent.

Authors: D David; E D Segni; H O Klein; E Kaplinsky
Journal: Am J Cardiol Date: 1979-12 Impact factor: 2.778

8. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil.

Authors: S Gulamhusein; P Ko; S G Carruthers; G J Klein
Journal: Circulation Date: 1982-02 Impact factor: 29.690

9. Verapamil in the management of supraventricular tachyarrhythmias occurring after a recent myocardial infarction.

Authors: F Hagemeijer
Journal: Circulation Date: 1978-04 Impact factor: 29.690

10. Paradoxic acceleration of ventricular rate after therapy with lidocaine and ajmaline. Findings in two patients with supraventricular tachyarrhythmia.

Authors: H O Klein; E D Segni; E Kaplinsky
Journal: Chest Date: 1977-04 Impact factor: 9.410

7 in total

Review 1. Atrial fibrillation. The therapeutic options.

Authors: R V Lewis
Journal: Drugs Date: 1990-12 Impact factor: 9.546

2. Influence of famotidine on verapamil pharmacokinetics in rats.

Authors: Kamal M Matar
Journal: Eur J Drug Metab Pharmacokinet Date: 2005 Jul-Sep Impact factor: 2.441

3. Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study.

Authors: Dagmar Busse; Silke Templin; Gerd Mikus; Matthias Schwab; Ute Hofmann; Michel Eichelbaum; Kari T Kivistö
Journal: Eur J Clin Pharmacol Date: 2006-07-04 Impact factor: 2.953

Review 4. Anti-Arrhythmic Agents in the Treatment of Atrial Fibrillation.

Authors: Omar F Hassan; Jassim Al Suwaidi; Amar M Salam
Journal: J Atr Fibrillation Date: 2013-06-30

Review 5. Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation.

Authors: Gerald V Naccarelli; John Hynes; Deborah L Wolbrette; Luna Bhatta; Mazhar Khan; Jerry Luck
Journal: Curr Cardiol Rep Date: 2002-09 Impact factor: 2.931

6. Development and in vivo floating behavior of verapamil HCl intragastric floating tablets.

Authors: Anand Patel; Moin Modasiya; Dushyant Shah; Vishnu Patel
Journal: AAPS PharmSciTech Date: 2009-03-19 Impact factor: 3.246

7. Clinical pharmacology of chronic atrial fibrillation.

Authors: R Lewis; J McClay
Journal: J R Coll Physicians Lond Date: 1988-10

7 in total